Meet with… Novartis Venture Fund

Jun 20 2017

Let's get more solutions to patients. The Johnson & Johnson Innovation, JLABS (JLABS) Meet with… Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities.

On June 20th Managing Director Steven Weinstein and Life Sciences Investment and Operations Professional Giovanni Ferrara of the Novartis Venture Fund (NVF)team will be in attendance to give an overview presentation about the fund's key areas of interest and to meet 1-on-1 with companies that have been accepted after applying online.

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due May 19, 2017. Apply Here.

Program Overview:
The Novartis Venture Fund founded in 1996, currently manages over $750 Million in committed capital, and has investments in ~40 portfolio companies globally. NVF's strategy is to build a diverse portfolio of life science companies, across:

  • Biotechnology/biopharma
  • Medical device/diagnostics
  • Digital/eHealth

NVF is stage agnostic and engages in seed investments as well as later-stage investments, typically investing up to $15 - $20 million over the life of the company. In investing, NVF looks for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency.

Following the presentation, don't miss this opportunity to introduce yourself to the team during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Novartis Venture Fund will provide an intimate forum to discuss your company

Steven Weinstein | Managing Director, Novartis Venture Fund read bio»

Giovanni Ferrara | Life Sciences Investment and Operations Professional, Novartis Venture Fund read bio»

10:30 AM | Registration and Networking
11:00 AM | Presentation and Q&A
11:45 AM | Networking Lunch
1:00 - 5:00 PM | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due May 19, 2017. Apply Here.

Speaker Bios:

Steven Weinstein | Managing Director, Novartis Venture Fund
Steve is a Managing Director in Novartis Venture Fund's Cambridge, MA office. He joined the Fund in 2006, and has been investing in venture capital since 1999.

He focuses on both medical device and bio/pharma investments for the fund. He brings significant operating and venture capital experience to Novartis' investing efforts. He has served on many boards including: Ablation Frontiers (acquired by Medtronic), Autonomic Technologies Inc., Innocrin Pharmaceuticals, Rox Medical, Sonitus Medical, Viamet Pharmaceuticals., and Visiogen (acquired by Abbott).

Prior to Novartis, Steve was at Prism Venture Partners, where he focused on medical devices and served on the board of Sensitech (acquired by Carrier/UTX). Prior to Prism, Steve was a Kauffman Fellow with Mid-Atlantic Venture Funds, where he focused on software startups. He started his career as an entrepreneur and CEO, raising angel funds to buy the assets of a defunct industrial distribution business out of bankruptcy. He then successfully restarted and built the business over the next five years.

Steve holds an M.B.A. with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University's School of Engineering and Applied Science. He serves on the Innovation Advisory Board of Partners Healthcare, is a member of the Virginia GAP BioLife Fund Investment Committee, and is on the advisory board of the Wolverine Venture Fund (affiliated with the University of Michigan).

Giovanni Ferrara | Life Sciences Investment and Operations Professional, Novartis Venture Fund
Giovanni Ferrara is a Venture Partner in Cambridge, MA, USA. He joined NVF from portfolio company Sorbent Therapeutics, where he was consulting Chief Business Officer and a consultant to leading west coast venture capital firms. Most recently, Giovanni was consulting Chief Business Officer to Sorbent Therapeutics. Previously, he was Managing Director and General Partner at Burrill & Company and began his venture capital career at GeneChem Management, where in addition to his investing responsibilities, he held operating positions in portfolio companies, including CEO of Targanta Therapeutics. He began his career in healthcare at a cancer treatment center researching experimental therapies. He received his MBA and MSc from McGill University. Giovanni serves on the boards of, E-scape, NeuroVia and Thesan Pharmaceuticals.


$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on June 20 (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Apply to meet one-on-one with representatives from Novartis Venture Fund.  Your application will be reviewed and you will be notified of acceptance on Monday June 6, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Map It